University of Thessaly (UTH)
Comparative study of the efficacy and safety between aminosidine (paromomycin) and meglumine antimonate for the treatment of canine leishmaniosis due to Leishmania infantum
Abstract
dc:descriptionCanine leishmaniosis is a zoonotic disease caused by the protozoan L. infantum (syn: L.chagasi) with a high prevalence of infection in many countries, including Greece. Current treatment recommendations for dogs without advanced kidney disease include the administration of meglumine antimoniate or miltefosine for 4 weeks along with allopurinol for at least 12 months. These combination treatments are relatively safe and lead to significant clinical and clinicopathological improvement, reduction of parasitic load and of Lesihmania-specific antibodies, and are accompanied by low relapse rates. Protozoan resistance to first-line drugs is a well-known problem in human medicine. In CanL, similar reports of drug resistance, although sparse, appear more and more commonly. Drug pressure (e.g. repeated administration of meglumine antimoniate and long-term allopurinol administration) are documented causes for the development of resistance. Due to the frequency of CanL in endemic areas and the zoonotic potential, investigations on alternative treatment options are urgently needed. Aminosidine (paromomycin) is an aminoglycoside antibiotic with leihmaniocidal properties that has been studied and used mainly in human leishmanioses. The efficacy and safety of aminosidine as monotherapy of CanL has been previously assessed in a small number of clinical trials. Despite some notable differences among the results of these studies, a good short-term clinical and clinicopathological response has been documented but it is accompanied by dose-related severe side effects and by a high relapse rate after treatment discontinuation. Recently, aminosidine administered at an optimized dose regimen (15 mg/kg, once daily, subcutaneously), resulted in effective plasma concentrations, good short-term clinical and clinicopathological improvement and reduction of parasitic load. To the best of our knowledge there are no published studies evaluating the efficacy of aminosidine-allopurinol combination for the treatment of CanL. However, similarly to the first-line drugs (meglumine antimoniate and miltefosine) the combination of aminosidine with allopurinol is probably mandatory to improve efficacy and, mainly, to avoid relapses. The aim of this randomized, blinded, controlled study was to compare the efficacy and safety of aminosidine-allopurinol combination with that of meglumine antimoniate-allopurinol, in terms of improvement of clinical signs and clinicopathological abnormalities, relapse rate, parasitic load reduction, evolution of Leishmania-specific humoral and cell mediated immune responses and side effects. Forty client-owned dogs with at least one clinical sign of CanL, without evidence of stage III or IV chronic kidney disease were randomly assigned to group A [n=20; aminosidine (15 mg/kg, subcutaneously, once daily for 28 days) and allopurinol (10 mg/kg, per os, twice daily for 6 months] or group B [n=20; meglumine antimoniate (100 mg/kg subcutaneously, once daily for 28 days) and allopurinol (same dose as in above)]. At enrollment (time 1) the dogs were physically examined and biological material were collected (blood, urine, lymph node and bone marrow aspirates). Re-examinations were scheduled after 15 (time 2), 30 (time 3), 60 (time 4) and 180 days (time 5). The examinations included: a) physical examination and scoring of the extent and severity all CanL-associated clinical signs (times 1-5); b) complete blood count including a manual differential count (times 1-5); c) complete serum biochemistry including C-reactive protein and c-cystatin (times 1-5); d) complete urinalysis including UPC (times 1-5) and urine culture (time 1); e) lymph node and bone marrow microscopy for measurement of parasitic density (times 1 and 3-5); f) IFAT (times 1 and 3-5); g) real-time PCR in bone marrow samples for measurement of parasitic density (times 1 and 3-5); h) LST (times 1 and 3-5); i) BAER testing (times 1-4). All examinations were conducted blindly regarding the group of each dog. During the first month (injectable treatment) all dogs were hospitalized and daily physical examinations were conducted by a non-blinded investigator who was also responsible for randomization and treatment administration. Primary outcome measures were the proportions of dogs that: a) experienced treatment-related side effects; b) were cured (no clinical signs, anemia, hypoalbuminemia, hyperglobulinemia or low AG ratio); and c) were parasitologically negative (lymph node and bone marrow microscopy and bone marrow RT-PCR) at the end of the trial. Secondary outcome measures were the proportions of dogs that a) were clinically cured (no clinical signs, irrespectively of the clinicopathological abnormalities); b) had no anemia, hypoalbuminemia, hyperglobulinemia, low AG ratio or increased C-reactive protein concentration; c) were seronegative; and d) were LST positive. There were no differences between groups for the primary outcome measures (treatment related side effects: p=1; cure: p=0.074; negative parasitological examinations: p=0.485). However, there were differences in some secondary outcome measures favor of group B: prevalence of clinical cure (p=0.044), hyperglobulinemia (p=0.008) and prevalence of seronegative dogs (p=0.02). On the other hand, the prevalence of anemia (p=0.189), hypoalbuminemia (p=1), decreased AG ratio (p=0.09), increased C-reactive protein concentration (p=0.074) and LST positivity (p=0.097). The aminosidine-allopurinol combination resulted in a significant improvement of clinical signs and clinicopathological abnormalities, a reduction of antibody titers and parasitic load and an increased prevalence of positive LST. The time and the probability to achieve these goals of treatment were not generally different between the groups.No significant nephrotoxic or ototoxic adverse events were observed in the dogs of the trial. Increases of creatinine concentration >0.3 mg/dl were recorded in both groups at a similar frequency.Based on these results aminosidine-allopurinol concentration should be considered a safe and effective treatment for CanL. Due to some differences in secondary outcome measures, it cannot be considered as equally effective with the meglumine antimoniate-allopurinol combination and, thus, it is proposed a second-line drug combination for the treatment of CanL.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kasabalis, Dimitris
- Κασαμπαλής, Δημήτριος
Subjects
dc:subject × 6Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/47480